Fulcrum Therapeutics (FULC) NDR Draws Significant Investor Interest Ahead of Ph1 Data - Stifel
Tweet Send to a Friend
Stifel analyst Dae Gon Ha reiterated a Buy rating and $39.00 price target on Fulcrum Therapeutics (NASDAQ: FULC) after hosting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
